Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation

Abstract

Targeting glutaminolysis with CB-839, metformin, phenformin or chloroquine is a potential therapeutic strategy for a subset of high-grade chondrosarcomas, irrespective of the presence or absence of an IDH1/2 mutation.